Physician profile
Jullius I Ancheta
NPI 1225146350
$2,860.73
in general payments reported to CMS, 2019-2025
31 companies · $910 in 2025
The $910 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $245 · 2023: $474 · 2024: $745 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,129.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $493.03 | 2023-2025 | Ubrelvy, Qulipta |
| Biogen, INC. | $282.85 | 2019-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $267.75 | 2019-2025 | Amyvid, Kisunla |
| Pfizer INC. | $227.75 | 2023-2025 | |
| Ucb, INC. | $161.73 | 2019-2025 | Zilbrysq, Rystiggo |
| Acorda Therapeutics, INC | $127.75 | 2020-2024 | Inbrija |
| Novartis Pharmaceuticals Corporation | $124.55 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $116.03 | 2019-2025 | Austedo Xr, Austedo Xr |
| Argenx US, INC. | $95.69 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Takeda Pharmaceuticals U.S.A., INC. | $93.98 | 2025 | Hyqvia |
| Eisai INC. | $90.71 | 2023-2025 | |
| Avanir Pharmaceuticals, INC. | $79.65 | 2019 | |
| Ge Healthcare | $71.73 | 2019-2025 | |
| Lundbeck LLC | $67.84 | 2024-2025 | Vyepti |
| Amgen INC. | $65.37 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $65.04 | 2025 | |
| Neurelis, INC. | $53.38 | 2023 | Valtoco |
| Allergan, INC. | $47.24 | 2020 | |
| Acadia Pharmaceuticals INC | $44.46 | 2023-2024 | Nuplazid |
| Emd Serono, INC. | $39.51 | 2019 | |
| Grifols USA, LLC | $38.12 | 2024-2025 | Gamunex-C |
| Alexion Pharmaceuticals, INC. | $26.60 | 2019 | |
| Merz Pharmaceuticals, LLC | $26.33 | 2025 | Inbrija |
| Genentech USA, INC. | $24.19 | 2019-2023 | Ocrevus |
| Sunovion Pharmaceuticals INC. | $22.32 | 2019 | |
| Cycle Pharmaceuticals INC | $21.00 | 2025 | Tascenso Odt |
| Supernus Pharmaceuticals, INC. | $19.50 | 2019 | |
| Amneal Pharmaceuticals LLC | $17.98 | 2024 | Crexont |
| C2n Diagnostics, LLC | $17.69 | 2025 | Precivityad2 |
| Arbor Pharmaceuticals, INC. | $16.05 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.91 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jullius Ancheta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.